Questionnaire Helps
Identify Women at Risk of Inherited Breast or Ovarian Cancer
Behind the Cancer Headlines®
A simplified way for patients to report and update their
family medical histories could help identify women who have inherited genetic
mutations that increase their risk for breast or ovarian cancer. In the journal
Cancer, researchers from the
Massachusetts General Hospital (MGH)
"In order to identify patients at high risk, physicians must take thorough family histories and then accurately interpret that information, something that can be difficult since many nuances can determine risk," says Kevin Hughes, MD, of the MGH Surgical Oncology Division, the study's senior author. "In addition, family history can change over time if a patient's relatives develop cancer. We need an easier way to both update data and reevaluate each patient's situation."
Previous research has shown that about 20 percent of women who develop breast or ovarian cancer have family histories that suggest they may have inherited a mutation that would put them at elevated risk. In comparison, the family histories of only 3 to 6 percent of women who had not developed those cancers indicate elevated risk. The current study was designed to further investigate the extent to which women with these mutations are not being identified and to evaluate a less labor-intensive method of collecting and analyzing family history information.
During the eight-month study period, about 14,000 women who
came to the
Among the 1,764 participants who had been diagnosed with breast or ovarian cancer, 20.6 percent had family histories indicating elevated risk of one of the tumor-associated mutations. Risk levels were even higher among participants who'd had ovarian cancer and those of Ashkenazi Jewish ancestry, a group known to have higher incidence of the mutations. The earlier study that found similar risk levels used a more complicated risk-assessment procedure conducted by a genetic counselor, a resource not available in many centers.
"We wanted to show we could identify these high-risk
women with an automated system that provides accurate information without
requiring more work for our staff, an approach that has been tried in very few
centers worldwide," says Hughes. "In addition to verifying the
utility of this strategy, these results remind us how many women who should be
tested for these genetic mutations are not being screened." Hughes is an
assistant professor of Surgery at
The researchers note that women diagnosed with the
cancer-associated mutations can pursue a number of options. Preventive
approaches include treatment with tamoxifen or
contraceptive drugs and prophylactic removal of the breasts or ovaries. More
frequent screenings with mammograms and MRI imaging can lead to early
diagnosis. And for those who develop tumors, mutation status can help determine
the best treatment strategies. The team is continuing to administer the
questionnaire to patients at the MGH and will begin doing so at
SOURCE:
Cancer, November
2005, published online